This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Illumina Offers FDA-Approved NGS Cancer Companion Test Kit
by Zacks Equity Research
Illumina, Inc. (ILMN) recently announced that its FDA-approved next-generation sequencing (NGS) -- Extended RAS Panel has met the Current Colorectal Cancer Guidelines.
Lantheus Holdings at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Lantheus Holdings, Inc. (LNTH), based in North Billerica, U.S., scaled a new 52-week high of $17.85 on Jun 30, eventually closing a bit lower at $17.65.
Envision Healthcare (EVHC) Acquires Anesthesia Associates
by Zacks Equity Research
Envision Healthcare Corporation (EVHC), recently announced that it has acquired Connecticut based anesthesia physician group practice, Anesthesia Associates of New London, P.C.
Boston Scientific Rides on New Growth Plans amid Headwinds
by Zacks Equity Research
On Jun 29 2017, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX).
Abaxis (ABAX) Product Portfolio Strong, Competition Rife
by Zacks Equity Research
On Jun 28, we issued an updated research report on California-based Abaxis, Inc. (ABAX).
BioScrip (BIOS) Strong on Infusion, Reimbursement a Drag
by Zacks Equity Research
On Jun 28, we issued an updated research report on Elmsford, NY-based BioScrip, Inc. (BIOS), a leading Infusion Service provider.
Walgreens (WBA) Tops Q3 Earnings, Scraps Rite-Aid Deal
by Zacks Equity Research
Walgreens Boots Alliance, Inc. (WBA) reported adjusted earnings per share (EPS) of $1.33 in third-quarter fiscal 2017, up 12.7% year over year.
Medtronic (MDT) Partners with Aetna for Type 1 & 2 Diabetes (Revised)
by Zacks Equity Research
Medtronic plc (MDT) inked a new outcomes-based collaboration with Aetna (AET) for type 1 and type 2 diabetes patients who are on doses of multiple daily insulin injections.
Zimmer Biomet (ZBH) Launches X-Ray-Based X-PSI Knee System
by Zacks Equity Research
Zimmer Biomet Holdings, Inc. (ZBH) recently launched a X-ray-based Patient Specific Instrument, X-PSI Knee System.
Walgreens Boots-LabCorp Tie Up for Patient Service Centers
by Zacks Equity Research
Walgreens Boots Alliance, Inc. (WBA), a major pharmacy-led, health and wellbeing enterprise, recently announced collaboration with leading diagnostic service provider LabCorp (LH).
IDEXX Well-Poised on Strong Fundamentals, Global Growth
by Zacks Equity Research
On 29, we issued an updated research report on IDEXX Laboratories, Inc. (IDXX).
Quest Diagnostics to Buy Outreach Lab Service in Cape Cod
by Zacks Equity Research
Quest Diagnostics Inc. (DGX) recently teamed up with Cape Cod Healthcare (CCHC) to obtain its outreach laboratory service business.
Hologic (HOLX) Product Pipeline Strong, Competition Rife
by Zacks Equity Research
On Jun 27, we issued an updated research report on Hologic, Inc. (HOLX), headquartered in Bedford, MA.
NuVasive (NUVA) Grappling with Odds: Should You Dump Stock?
by Zacks Equity Research
On Jun 28, we issued an updated research report on San Diego, CA-based NuVasive, Inc. (NUVA), a major player in the global spine market.
Ensign Group (ENSG) Acquires Facilities in Texas & Wisconsin
by Zacks Equity Research
The Ensign Group, Inc. (ENSG) recently announced that it acquired the real estate and operations of two assisted living facilities in Texas and three assisted living facilities in Wisconsin.
Medtronic (MDT) Partners with Aetna for Type 1 & 2 Diabetes
by Zacks Equity Research
Medtronic plc (MDT) recently inked a new 'outcomes-based' collaboration with Aetna (AET) for type 1 and type 2 diabetes patients who are on doses of multiple daily insulin injections.
Thermo Fisher Gets FDA's PMA for Oncomine Dx Target Test
by Zacks Equity Research
Thermo Fisher Scientific Inc. (TMO), a leading scientific instrument maker, recently received premarket approval (PMA) from the U.S. FDA for its Oncomine Dx Target Test.
Walgreens (WBA) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Walgreens Boots Alliance, Inc. (WBA) is slated to release third-quarter fiscal 2017 results before the market opens on Jun 29.
Penumbra (PEN) at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Penumbra, Inc. (PEN), headquartered in Alameda, CA, scaled a new 52-week high of $91 on Jun 26, eventually closing a little lower at $86.95.
Quest Diagnostics Enhances Blueprint for Athletes Service
by Zacks Equity Research
Quest Diagnostics Inc. (DGX), a global provider of clinical lab services, recently expanded its biomarker testing service known as Blueprint for Athletes.
Why Investors Should Buy Align Technology (ALGN) Right Now
by Zacks Equity Research
Align Technology, Inc. (ALGN), the designer and manufacturer of Invisalign System, has rallied 51.9% over the last six months, ahead of the S&P 500's 7.9% gain.
Cooper Companies (COO) Hits 52-Week High on Solid Prospects
by Zacks Equity Research
The Cooper Companies (COO) rallied to a new 52-week high of $247.80 on Jun 22, closing a tad lower at $245.06.
Why Hold Strategy is Apt for Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Thermo Fisher Scientific, Inc. (TMO) has rallied 13.5% over the past three months, ahead of the S&P 500's mere 4.3% gain.
Here's Why Henry Schein is Worth Adding to Your Portfolio
by Zacks Equity Research
Over the last six months, Henry Schein Inc. (HSIC) was consistently trading ahead of the S&P 500 Index.
Bio-Rad (BIO) Scores a Strong Buy Right Now: Here's How
by Zacks Equity Research
Bio-Rad Laboratories, Inc. (BIO) has rallied 12.9% over the last three months, ahead of the S&P 500's 4.3% gain.